The largest insider buy on today’s list is a Form 4 filing by Michael Gladstone, independent director at Day One Biopharmaceuticals $DAWN.

Gladstone disclosed the purchase of approximately $11.5 million worth of shares in the mid-cap biotech...

SkyKnight Capital Fund disclosed the purchase of approximately $1.6 million worth of shares in the home medical equipment company AdaptHealth Corp $AHCO, as it continues to build a position in the stock.

The fund now owns 8,906,070 shares,...

The market correction has extended over the past few weeks and the negative sentiment build-up is definitely not something that will fade away quickly. As more and more sectors move below their support zones, buy ideas are hard to come by. Today we're...

The largest insider transaction on today’s list comes in a Form 4 filing from Allied Physicians of California.

The firm reported a purchase of roughly $9.2 million in Apollo Medical Holdings $AMEH. It now owns about 11 million shares for a...

How's the Bear Market treating you?

We're going on over 16 months of this so far, and counting....

Remember, ...

William Griffith, director of Procore Technologies $PCOR, reported an additional purchase of roughly $7 million, as he continues to build his position in the stock.

Under Iconiq Strategic Partners II, he now owns about 44 million shares for a...

We give them fancy names like Bear Markets or Downtrends.

But all it really means is that the price of an asset is below overhead supply.

The big activist news of the day is that Elon Musk is reportedly still at work on his Twitter deal.

The eccentric...

The largest insider transaction on today's list is a Form 4 filing by Ernest Garcia II, CEO and co-founder of Carvana $CVNA.

Garcia II reported an additional purchase of roughly $42 million of his own stock.

The largest insider buy on today’s list is a Form 4 filing by David Goeddel, independent director at NGM Biopharmaceuticals $NGM.

Goeddel disclosed the purchase of approximately $13.2 million worth of shares in the small-cap biotech company...

The market has been finding it excruciatingly difficult to hold don to higher levels. This time we have a sell signal coming from another big name. Let's take a look at this, shall we?